Study finds nitric oxide does not help sickle cell pain crisis

March 1, 2011

Inhaling nitric oxide gas does not reduce pain crises or shorten hospital stays in people living with sickle cell disease, according to the results of a new study sponsored by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health.

" for Inhalation in the Acute Treatment of Sickle Cell Pain Crisis," will be published in the March 2 issue of the .

is an inherited disorder affecting between 70,000 and 100,000 Americans. The disease causes , which are normally disc-shaped and pliable, to become misshapen, stiff and sticky. Severe pain crises occur periodically in people living with sickle cell disease when these sickled red blood cells hinder proper blood flow.

Nitric oxide dilates and expands and enhances blood flow. Levels are lower in persons with sickle cell disease than in those without the disease. Previous trials with smaller numbers of patients had suggested that administration of nitric oxide might shorten sickle cell pain crises.

This study involved 150 sickle cell disease patients who were hospitalized for severe pain crises. Each participant was given nitric oxide gas or a placebo gas during treatment. Though the nitric oxide was well-tolerated, it failed to improve outcomes. The average length of pain crises among trial participants was 73 hours in the nitric oxide group compared with 65.5 hours in the placebo group, which was not statistically different. There was also no statistical difference between the two groups in average length of hospital stay or average painkiller usage.

Explore further: Reducing side-effects of painkillers

More information: Learn more about this trial at: clinicaltrials.gov/ct2/show/NCT00094887

JAMA. 2011;305[9]893-902.

Related Stories

Reducing side-effects of painkillers

September 12, 2006

Cardiff University researchers have increased the understanding of why some painkillers increase the risk of heart attack and stroke.

Sickle cell treatment enters Phase 3 clinical trial

July 23, 2010

An experimental treatment for sickle cell disease developed at the Los Angeles Biomedical Research Institute (LA BioMed) has entered Phase 3 clinical trials, David I. Meyer, PhD, LA BioMed president and CEO announced today.

Compound may prevent sickle cell pain crises

February 1, 2011

A new compound appears to prevent the traffic jam of cells that causes debilitating pain crises and associated mortality in sickle cell disease, Georgia Health Sciences University (formerly Medical College of Georgia) researchers ...

Recommended for you

How the finch changes its tune

August 3, 2015

Like top musicians, songbirds train from a young age to weed out errors and trim variability from their songs, ultimately becoming consistent and reliable performers. But as with human musicians, even the best are not machines. ...

Machine Translates Thoughts into Speech in Real Time

December 21, 2009

(PhysOrg.com) -- By implanting an electrode into the brain of a person with locked-in syndrome, scientists have demonstrated how to wirelessly transmit neural signals to a speech synthesizer. The "thought-to-speech" process ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.